Viking Therapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $8.8M | $210.7M | $26.4M |
| FY2022 | $23.2M | $168.5M | $36.6M |
| FY2023 | $20.1M | $368.5M | $55.5M |
| FY2024 | $28.0M | $908.3M | $26.7M |
| FY2025 | $76.7M | $715.7M | $165.8M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $8.8M | $210.7M | $26.4M |
| FY2022 | $23.2M | $168.5M | $36.6M |
| FY2023 | $20.1M | $368.5M | $55.5M |
| FY2024 | $28.0M | $908.3M | $26.7M |
| FY2025 | $76.7M | $715.7M | $165.8M |